Therma Bright (TSE:THRM) has released an update.
Therma Bright Inc. celebrates a significant advancement in stroke and blood clot treatment as its investment portfolio company, Inretio, successfully completes the third human trial of the Preva device, a novel clot removal technology. The Preva device stands out for its precision and safety in ischemic stroke care, offering a promising alternative to traditional methods and positioning Therma Bright for potential growth in the global coronary stents market.
For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.
